Myasthenia gravis: the changing treatment landscape in the era of molecular therapies
Crossref DOI link: https://doi.org/10.1038/s41582-023-00916-w
Published Online: 2024-01-08
Published Print: 2024-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Iorio, Raffaele
Text and Data Mining valid from 2024-01-08
Version of Record valid from 2024-01-08
Article History
Accepted: 6 December 2023
First Online: 8 January 2024
Competing interests
: The author has received consultancy fees and speaker honoraria from Alexion, Argenx and UCB.